Navigation Links
Today(R) Sponge to be Distributed in Hong Kong and Macau
Date:11/8/2007

MEDIA, Pa., Nov. 8 /PRNewswire-FirstCall/ -- Synova Healthcare Group, Inc. (OTC Bulletin Board: SNVH) announced today that it would begin distributing and selling its Today(R) Sponge non-hormonal contraceptive product in Hong Kong and Macau through Hind Wing Co, Ltd., a distributor located in Hong Kong. This represents an important milestone for the Company, as it will be the first time Synova has made the Today(R) Sponge available to women outside North America. Synova expects to begin shipping to Hind Wing before the end of the year.

Hind Wing is one of the largest pharmaceutical trading companies in Hong Kong. Hind Wing represents a wide range of well-known pharmaceuticals, diagnostics, and medical and consumer products that are manufactured in North America, Europe, Japan and Australia. Its selling network represents professional and consumer products in private and government hospitals, medical clinics, independent pharmacies, pharmacy chains, family planning association clinics, department and baby stores.

Thomas Lun, General Manager of Hind Wing, noted, "We are excited about initiating distribution of the Today(R) Sponge in Hong Kong and Macau. In addition to our local consumer marketing programs, we plan to support the launch by conducting educational training sessions with physicians, pharmacist associations, and the Hong Kong Family Planning Association."

Stephen E. King, Chairman and CEO of Synova stated, "The Today(R) Sponge can be an important contraceptive option for women in many markets around the world. Given Hind Wing's impressive distribution network, professional sales team, and experience in marketing contraceptive and medical products, we believe that it will prove to be a successful distribution partner for Synova."

About Synova Healthcare Group, Inc.

Synova Healthcare Group, Inc. is committed to delivering innovative products that provide meaningful improvements in women's healthcare. Through its subsidiaries, it is focused on the development, distribution, marketing and sale of women's healthcare products related to contraception, vaginal health, menopause management, fertility planning, obstetrics and personal care. Its goal is to provide healthcare solutions that address every stage of a woman's life.

Synova currently markets and sells products under the brand names Today(R), Fem-V(R) and MenoCheck(R). The Today(R) Sponge is a hormone-free contraceptive that combines barrier, spermicidal and absorptive methods to prevent conception. Fem-V(R) is a non-invasive diagnostic test designed to assist women in detecting and diagnosing the presence of elevated vaginal acidity, often indicating a vaginal infection. MenoCheck(R) is an in-home, non-invasive diagnostic test used to detect and diagnose the onset of menopause. For more information, please visit the Company's website at http://www.synovahealthcare.com.

About Hind Wing Co, Ltd.

Established in 1979 by a team of pharmacists, Hind Wing is a leading pharmaceutical and medical distributor in Hong Kong, Macao, Southern China cities such as Shenzhen, Zhuhai, Guanzhou and Foshan in Guandong Province. Hind Wing represents a wide range of well-known brands of pharmaceuticals, diagnostics, medical and consumer products manufactured in North America, Europe, Japan and Australia, including those manufactured by roha arzneimittel, GmbH, in Germany, SANDOZ, in Switzerland and Apotex Inc., in Canada. Hind Wing has a broad selling network which includes professional and consumer sales specialists covering Hong Kong, Macao and Southern China for private and government hospitals, medical and dental clinics, independent and pharmacy chains, the Hong Kong family planning association and department stores and baby stores.

This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates", "believes", "estimates", "expects", "plans", "intends", "potential" and similar expressions. These statements reflect the Company's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. Such risks and uncertainties include our ability to successfully market, distribute and sell our products, the acceptance of our products by consumers, our ability to expand our retail distribution network, our ability to compete against similar or other women's healthcare products and the other risks and uncertainties discussed in the Company's Form 10-KSB for the year ended December 31, 2006, as filed with the Securities and Exchange Commission on February 26, 2007, and as amended on November 7, 2007, and the Company's Form 10-QSB for the six months ended June 30, 2007, as filed with the SEC on August 14, 2007, as well as in the Company's other periodic reports and filings with the SEC. There can be no assurance that such factors will not affect the accuracy of such forward- looking statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information set forth in this Press Release including such forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sale of securities of Synova Healthcare Group, Inc. in any state where such offer, solicitation or sale would be unlawful before registration or qualification under the securities laws of those states.


'/>"/>
SOURCE Synova Healthcare Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. MedPage Today(R) Continuing Medical Education Activities Now Offer AAPA Credit for Physician Assistants
2. AmeriCares Passes $7 Billion Mark in Aid Distributed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/24/2017)... ... August 24, 2017 , ... Lori ... the development and advances in Desensitization therapy to improve the outcomes of organ ... about his remarkable journey of his 25 years of research in developing therapies ...
(Date:8/24/2017)... ... August 24, 2017 , ... Prime candidates for home ... have a condition that needs further monitoring such as surgery, stroke, heart attack ... stable, such as diabetes, high blood pressure, heart/lung disease, arthritis and stroke. ...
(Date:8/23/2017)... ... 2017 , ... The Arc Mercer, Capitol County’s premier provider of programs and ... community organization for people with special needs. The group, the Special Needs Alliance for ... of New Jersey – but the first in the entire country! , SNAP was ...
(Date:8/23/2017)... ... 2017 , ... Drs. Steven White and Brad Haines are pleased to announce ... of this offer, valued at more than $300 per year, new patients can enjoy ... patients receive a complimentary professional whitening procedure. , Stained or yellowed tooth enamel ...
(Date:8/23/2017)... ... ... Awards have announced the winners of the Best of the IBA Awards in The 2017 ... in the 2017 IBAs were not able to apply for the Best of the IBA ... awards won in the IBAs with a Gold Stevie win counting for three points, a ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... 2017   Mostyn Law and Gulf Coast Regional Blood ... . The Mostyn Law family has had 3 ... is why Mostyn Law is partnering with Gulf Coast ... its appreciation. Blood supplies are running low. Gulf Coast ... hospital needs in August. That is why the blood center reached ...
(Date:8/15/2017)... , Aug. 15, 2017  AOTI Inc. announced today that ... Therapy Inc., has recently opened a New York City Office in ... usage of its unique Topical Wound Oxygen (TWO 2 ) homecare ... the Accreditation Commission for Health Care (ACHC) under the company,s DMEPOS ... ...
(Date:8/8/2017)... -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused ... for the second quarter ended June 30, 2017. ... and to date: ... Company,s lead project, BL-8040: Announced plans ... novel stem cell mobilization treatment for autologous bone-marrow transplantation ...
Breaking Medicine Technology: